US 7572893
IL-1 antagonist formulations
granted A61KA61K38/1709A61K38/1793
Quick answer
US patent 7572893 (IL-1 antagonist formulations) held by REGENERON PHARMACEUTICALS, INC. expires Mon Aug 06 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Aug 11 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 06 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K38/1709, A61K38/1793, A61K38/2006, A61K47/183